Cancer-Focused Blueprint Medicines Prepares $115M IPO
Venture capital-backed Blueprint Medicines Corp., led by Goodwin Procter LLP, set terms on Monday to draw roughly $115 million in its initial public offering, setting the stage for the latest cancer-focused...To view the full article, register now.
Already a subscriber? Click here to view full article